On February 21, 2023 Novavax, Inc. (Nasdaq: NVAX), a global vaccines company advancing protein-based vaccines with its novel Matrix-M adjuvant, reported it will report its fourth quarter and full year 2022 financial results and operational highlights on Tuesday, February 28, 2023, following the close of U.S. financial markets (Press release, Novavax, FEB 21, 2023, View Source,-2023 [SID1234627477]). Details of the event and replay are as follows:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference call details:

Date:

February 28, 2023

Time:

4:30 p.m. U.S. Eastern Standard Time (EST)

Dial-in number:

(833) 974-2381 (Domestic) or (412) 317-5774 (International)

Webcast:

ir.novavax.com/events

Participants will be prompted to request to join the Novavax, Inc. call.
To ensure a timely connection, it is recommended that participants join at least 10 minutes prior to the scheduled webcast.
Replay details:

Date:

Available starting at 7:30 p.m. EST, February 28, 2023 until 11:59 p.m. U.S. EST, March 7, 2023

Dial-in number:

(877) 344-7529 (Domestic) or (412) 317-0088 (International)

Passcode:

1137418

Webcast:

ir.novavax.com/events, until May 28, 2023